
JPM 2026: Less talk and more action
‘JPM 2026’ certainly felt different to recent editions of the conference. The sky was blue – and the XBI had nearly doubled over the previous nine months. There’s nothing like a little winter sun and booming stocks to put a spring in an executive’s step! But questions over the robustness of the biopharma sector remain – to be expected after… Read More













